Open Access831 Serum Biomarkers Are Associated With Endoscopic and Clinical Outcomes in Crohn’s Disease Patients Receiving Vedolizumab Therapy
Author(s) -
Ariela Holmer,
Robert Battat,
Parambir S. Dulai,
Niels Vande Casteele,
Jennifer Neill,
Helen N. Le,
A Miralles,
Anjali Jain,
Kelly D. Hester,
Siddharth Singh,
Jesús Rivera–Nieves,
William J. Sandborn,
Brigid S. Boland,
Nghia Nguyen
Publication year - 2019
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000592860.82828.d8
Subject(s) - vedolizumab , medicine , addressin , crohn's disease , gastroenterology , biomarker , cohort , clinical trial , faecal calprotectin , disease , inflammatory bowel disease , integrin , calprotectin , biochemistry , chemistry , receptor